Minerva Neurosciences, Inc.: 10-Q filed 2017-05-04
What Minerva Neurosciences, Inc. reported in its quarterly report filed 2017-05-04 (fiscal Q1 2017): 20 published measures, 44 facts as tagged in accession 0001564590-17-008545.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-05-04
- Fiscal period
- fiscal Q1 2017
- Accession
- 0001564590-17-008545 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Minerva Neurosciences, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 135,306,613 | USD | |
| At 2016-12-31 | 132,942,889 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 29,020,360 | USD | |
| At 2016-12-31 | 26,960,681 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 106,286,253 | USD | |
| At 2016-12-31 | 105,982,208 | USD | |
| At 2016-03-31 | 66,649,449 | USD | |
| At 2015-12-31 | 55,319,557 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 68,894,824 | USD | |
| At 2016-12-31 | 82,980,609 | USD | |
| At 2016-03-31 | 34,822,042 | USD | |
| At 2015-12-31 | 14,284,054 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -10,644,596 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -8,004,410 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -143,502,830 | USD | |
| At 2016-12-31 | -132,858,234 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 6,338 | USD | |
| At 2016-12-31 | 9,640 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 1,310,043 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 790,228 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -10,485,073 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -7,756,906 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 86,230,876 | USD | |
| At 2016-12-31 | 83,863,850 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 12,986,042 | USD | |
| At 2016-12-31 | 9,685,859 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 3,275,442 | USD | |
| At 2016-12-31 | 1,468,341 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 14,869,399 | USD | |
| At 2016-12-31 | 14,869,399 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 10,485,073 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 7,756,906 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 7,614,331 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 5,374,864 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 36,704,872 | shares | |
| At 2016-12-31 | 35,024,002 | shares |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 34,200,000 | USD | |
| At 2016-12-31 | 34,200,000 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 2,870,742 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 2,382,042 | USD | 91 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 3,302 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 4,320 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 1,807,101 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -136,610 | USD | 91 |
Inspect the source
- Entity
- Minerva Neurosciences, Inc. / CIK 0001598646
- Captured
- 2026-09-20T09:25:02.110Z
- SEC response SHA-256
7b57da641574943cc8f7ca81f9c94ea1ff7a872915407c01165fb2137ec7efc4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001598646.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))